GlaxoSmithKline and Genmab Submit Arzerra (Ofatumumab) Application to FDA for the Treatment of Advanced Stage Blood Cancer

January 30, 2009 -- GlaxoSmithKline and Genmab A/S announced today the submission of a Biologics License Application to the U.S. FDA for Arzerra (ofatumumab) to treat patients whose chronic lymphocytic leukemia (CLL) is resistant (refractory) to previous therapies.
The details can be read here.